Ocugen shares tumble 7% on revenue miss, cash burn concerns
Clinical-stage biotech reports $0.2M loss vs $0.88M expected, cash reserves shrink to $18.9M
Ocugen shares plunged approximately 7% in pre-market trading on Wednesday after the clinical-stage biotechnology company reported fourth-quarter revenue that missed analyst expectations by a wide margin, intensifying investor concerns about the company's cash burn rate.
The Malvern, Pennsylvania-based company reported quarterly revenue of negative $0.19 million, falling short of the $0.88 million consensus estimate. The net loss per share came in at $0.06, which was in line with analyst projections, according to earnings coverage published March 4, 2026.
More concerning for investors was the significant deterioration in Ocugen's financial position. Cash and restricted cash fell to $18.9 million as of December 31, 2025, a sharp decline from $58.8 million at the end of 2024. The company did, however, secure $22.5 million in gross proceeds through a registered direct offering in January 2026, which extends its cash runway into the fourth quarter of 2026. The offering priced at $1.50 per share for 15 million shares, yielding net proceeds of approximately $20.85 million after expenses.
Despite the financial challenges, Ocugen highlighted progress in its clinical pipeline. The company completed enrollment in its Phase 3 liMeliGhT clinical trial for OCU400, a modifier gene therapy targeting retinitis pigmentosa. The trial enrolled 140 patients, with topline data anticipated in the first quarter of 2027. Ocugen plans to file a rolling Biologics License Application for OCU400 in the third quarter of 2026.
The company also reported positive preliminary data for OCU410, its gene therapy candidate for geographic atrophy secondary to dry age-related macular degeneration. Phase 2 data showed a 46% reduction in lesion growth at 12 months in the combined medium and high-dose groups compared to the control group. The complete dataset from the ArMaDa trial is expected in March 2026, with Phase 3 initiation planned for later this year.
Analysts maintain a cautiously optimistic outlook on the stock despite the earnings disappointment. The five analysts covering Ocugen rate the stock a consensus Buy, with an average price target of $9.00, according to market data as of March 3, 2026. The shares currently trade around $1.93, giving the company a market capitalization of approximately $635 million.
The steep drop in cash reserves underscores the challenges facing clinical-stage biotechnology companies, which must fund expensive research and development programs while generating little to no revenue. Ocugen's price-to-sales ratio of 118.25 reflects investor expectations of future commercial success rather than current financial performance.
The company's high beta of 2.81 indicates the stock's significant volatility, which was on display in Wednesday's pre-market session. Ocugen's 52-week trading range spans from $0.52 to $1.96, with the current pre-market decline threatening to test the lower end of that range.
Investors will be watching closely for the complete Phase 2 data on OCU410 expected this month, as well as updates on the company's capital allocation strategy following the January financing. With cash runway now extended to late 2026, Ocugen has limited time to demonstrate clinical progress that could support another fundraising round or partnership agreement.